EIF2AK2 and early-onset autosomal dominant Alzheimer disease: Variants in EIF2AK2 have been linked to neurodevelopmental and neurodegenerative disorders, and its inhibition has shown promise in improving cognitive deficits in Alzheimer’s disease models, suggesting a potential therapeutic avenue (32, 33).